Novel Drug for Treatment of Type 2 Diabetes: Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal.
In the United States, 1 in 10 individuals has diabetes, which affects how the body processes food into energy. One potential therapy is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide receptor agonist (GLP-1) that aims to control blood sugar. Injected under the skin, GLP-1 and GIP receptors cause the pancreas to release insulin and block the hormone glucagon, limiting blood sugar spikes after a meal. Additionally, it slows digestion, resulting in individuals remaining full longer and eating less. Thus far, late phase III clinical trials reveal that the treatment significantly reduces hemoglobin A1C in type 2 diabetes and supports weight loss, making it potentially the most effective therapy for diabetes and obesity yet developed.
Latest from Today's Medical Developments
- Building, maintaining the Navy’s next generation of maritime platforms
- Pioneering battery-free cardiac implants
- KBC Tools & Machinery marks its 60th anniversary, Founder’s Day
- Address the challenges of machining high-temperature aerospace components
- Elevate your manufacturing operations with April’s Manufacturing Lunch + Learn
- AdvaMed statement on tariff announcement
- Collets – Not all are created equal
- ENGEL expands production capacities in the Americas; new plant opened in Mexico
